Principal Financial Group Inc. Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Principal Financial Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,625 shares of the biopharmaceutical company’s stock after acquiring an additional 1,142 shares during the quarter. Principal Financial Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $92,335,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in REGN. Dodge & Cox raised its stake in shares of Regeneron Pharmaceuticals by 18.9% during the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after acquiring an additional 724,562 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after acquiring an additional 606,612 shares in the last quarter. Invesco Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after buying an additional 408,649 shares during the period. Caisse de depot et placement du Quebec increased its stake in shares of Regeneron Pharmaceuticals by 115.4% in the third quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company’s stock worth $260,051,000 after buying an additional 247,780 shares during the period. Finally, Man Group plc increased its stake in shares of Regeneron Pharmaceuticals by 257.6% in the third quarter. Man Group plc now owns 271,707 shares of the biopharmaceutical company’s stock worth $152,773,000 after buying an additional 195,724 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 2.7%

REGN stock opened at $721.05 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The company has a market capitalization of $76.23 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.57 and a beta of 0.30. The business has a 50 day simple moving average of $753.94 and a two-hundred day simple moving average of $739.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the prior year, the company posted $8.22 EPS. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.85 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on REGN. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research note on Thursday, April 30th. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Royal Bank Of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a report on Thursday, April 30th. Piper Sandler assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an “overweight” rating and a $875.00 target price on the stock. Finally, TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $826.59.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,874 shares of company stock worth $3,013,262 in the last three months. 6.97% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.